Artificial Intelligence in Early Detection of Skin Cancer through Dermoscopic Image Analysis

43 Eurasian J. Chem. Med. Pet. Res., (2026), Volume 5, Issue 1, 43-53 Artificial Intelligence in Early Detection of Skin Cancer through Dermoscopic Image Analysis Ali Azarkaman1*, Ali Jamali Nazari2 1Department of biomedical engineering, “Islamic Azad University, Tehran Central Branch, Tehran, Iran 2Department of biomedical engineering, Sha. C., Islamic Azad University, Shahrood, Iran Article info Received: 09.10.2025 Accepted: 2.10.2025 Available Online: 30.10.2025 Checked for Plagiarism: Yes Keywords: Artificial Intelligence, Skin Cancer, Ceroscopy, Deep Learning, Early Detection A B S T R A C T Skin cancer, particularly melanoma, poses significant health risks globally. Early detection is crucial for effective treatment and improved patient outcomes. Dermoscopy, a non-invasive imaging technique, has enhanced dermatologists' ability to examine skin lesions. Recent advancements in artificial intelligence (AI), especially deep learning, have shown promising results in automating the analysis of dermoscopic images for skin cancer detection. AI models, particularly convolutional neural networks (CNNs), have been trained on large datasets of dermoscopic images, achieving diagnostic accuracies comparable to or surpassing those of experienced dermatologists. These AI systems can assist in identifying malignant lesions, thereby aiding in early diagnosis and reducing the workload on healthcare professionals. However, challenges remain, including the need for diverse and representative datasets, addressing biases in AI models, and ensuring the clinical applicability of these technologies. This paper reviews the current state of AI applications in dermoscopic image analysis for skin cancer detection, discusses the methodologies employed, evaluates the performance of various AI models, and examines the potential impact on clinical practice. The integration of AI into dermatology holds the promise of enhancing diagnostic accuracy, improving patient outcomes, and optimizing healthcare resources. Introduction Skin cancer is among the most prevalent forms of cancer worldwide, with melanoma accounting for the majority of skin cancer-related deaths due to its high metastatic potential and aggressive nature. The incidence of skin cancer has been steadily rising over the past decades, influenced by factors such as increased ultraviolet (UV) exposure, lifestyle changes, and population aging [1]. According to the World Health Organization (WHO), approximately 132,000 melanoma cases are diagnosed annually, and non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma, contribute to a significantly higher global burden. Early detection is crucial, as the prognosis of skin cancer is strongly correlated with the stage at diagnosis. Melanoma detected at an early stage can be effectively treated through surgical excision, leading to survival rates exceeding 90%. In contrast, late-stage melanoma is associated with poor prognosis and limited treatment options, emphasizing the critical need for timely and accurate diagnosis [2]. Ceroscopy, also known as dermatoscopy or epiluminescence microscopy, has emerged as a transformative tool in the clinical evaluation of skin lesions. Unlike standard visual inspection, ceroscopy allows clinicians to visualize subsurface structures of the epidermis and dermis, revealing features such as pigment networks, vascular patterns, and morphological asymmetries that are indicative of malignancy. Numerous studies have demonstrated that dermoscopic evaluation significantly improves diagnostic accuracy, Eurasian Journal of Chemical, Medicinal and Petroleum Research Journal homepage: https://www.ejcmpr.com/ *Corresponding Author: Ali Azarkaman ([email protected]) 1 Email: Alij[email protected]m) 44 Eurasian J. Chem. Med. Pet. Res., (2026), Volume 5, Issue 1, 43-53 reducing the rates of unnecessary biopsies while enhancing early melanoma detection [3]. However, the effectiveness of ceroscopy is highly dependent on the clinician’s expertise, training, and experience. Misinterpretation of dermoscopic images, inter-observer variability, and diagnostic fatigue remain substantial barriers, particularly in regions with limited access to dermatological specialists. The rapid advancement of artificial intelligence (AI) in recent years has introduced new possibilities for automating and enhancing skin cancer detection. AI encompasses a range of computational techniques that allow machines to learn from data, identify patterns, and make predictions. Within the domain of medical imaging, deep learning particularly convolutional neural networks (CNNs) has demonstrated remarkable capability in image recognition tasks, including the classification of skin lesions. CNNs are specifically designed to automatically extract hierarchical features from images, enabling the identification of subtle patterns that may be difficult for human observers to detect. This capability is particularly relevant in dermatology, where early malignant changes in melanocytic lesions may present with minute visual cues that are challenging to interpret [4]. The integration of AI into dermoscopic image analysis offers several potential advantages. First, AI can enhance diagnostic consistency by providing standardized evaluations, reducing inter-observer variability among clinicians. Second, AI systems can process large volumes of images rapidly, enabling efficient screening and triage of high-risk lesions. Third, AI may serve as an educational tool for clinicians, offering feedback and decision support that enhances training in dermoscopic interpretation. Landmark studies, such as those conducted by Esteva et al. (2017) and Haenssle et al. (2018), have demonstrated that AI models can achieve dermatologist-level accuracy in classifying skin lesions, including both melanoma and nonmelanoma types. These findings underscore the potential of AI to transform the early detection landscape, particularly in settings where expert dermatological assessment is scarce [5]. Despite these promising developments, several challenges and limitations must be addressed to fully realize the potential of AI in clinical practice. A major concern is the availability of large, diverse, and well-annotated datasets necessary to train robust AI models. Many current datasets are biased toward fair-skinned populations, potentially reducing model performance in individuals with darker skin types and contributing to healthcare disparities. Additionally, AI models often operate as "black boxes," providing high accuracy predictions without transparent explanations of decision-making processes. This lack of interpretability can hinder clinician trust and adoption. Ethical considerations, including patient privacy, informed consent, and accountability for diagnostic errors, further complicate the clinical deployment of AI-based diagnostic tools [6]. Moreover, integrating AI into real-world clinical workflows requires careful consideration of the interplay between human expertise and machine intelligence. AI should be viewed as an augmentative tool rather than a replacement for clinical judgment. The development of hybrid diagnostic systems that combine AI predictions with clinician evaluation has been proposed to optimize diagnostic accuracy while maintaining accountability. Multimodal approaches that incorporate patient history, genetic information, and dermoscopic imagery may further enhance predictive performance, offering personalized risk assessments and guiding clinical decision-making. In addition to technical and ethical challenges, regulatory frameworks play a pivotal role in determining the deployment and adoption of AI in dermatology. Agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have established guidelines for the validation, certification, and monitoring of AI-driven medical devices. Ensuring compliance with these regulations is critical to ensure patient safety, clinical efficacy, and public trust [7]. Looking forward, the future of AI in skin cancer detection is likely to be shaped by several emerging trends. Federated learning, which allows AI models to be trained across decentralized datasets without sharing sensitive patient data, represents a promising approach to address privacy concerns while enhancing model generalizability. The development of explainable AI methods will enable clinicians to understand the rationale behind AI predictions, fostering trust and informed decision-making (Table 1). Additionally, integration with mobile ceroscopy devices and tele dermatology platforms has the potential to expand access to early detection services in underserved regions, promoting equitable healthcare delivery on a global scale [8]. 45 Eurasian J. Chem. Med. Pet. Res., (2026), Volume 5, Issue 1, 43-53 Table 1. Summary of Previous Studies No. AI Technique / Model Dataset Used No. of Images Key Metrics (Accuracy / AUC / Sensitivity) Major Findings 1 Deep CNN (Inception-v3) ISIC + DermNet ~129,000 Acc. 0.91 / AUC 0.96 First large-scale study; CNN matched dermatologist-level performance. 2 ResNet-50 HAM10000 10,015 Acc. 0.86 / AUC 0.95 CNN outperformed 58 dermatologists in melanoma classification. 3 Ensemble CNN (ResNet + Inception) ISIC Archive 25,000 AUC 0.94 / Sens. 0.88 Combining architectures improved robustness on external datasets. 4 EfficientNet-B0 HAM10000 + PH2 12,000 Acc. 0.91 / Sens. 0.89 Showed transfer learning effective for dermoscopic images. 5 MobileNetV2 HAM10000 10,015 Acc. 0.87 / AUC 0.90 Lightweight model for mobile/tele dermatology screening. 6 Vision Transformer (ViT-small) ISIC 2020 33,000 Acc. 0.89 / AUC 0.93 Transformer captured global lesion context better than CNN. 7 U-Net + SVM PH2 2,000 Acc. 0.84 / Sens. 0.80 Combined segmentation + classification improved interpretability. 8 CNN + Bayesian Optimization HAM10000 10,015 Acc. 0.90 / Sens. 0.88 Automated hyper parameter tuning improved convergence and precision. 9 Ensemble (ResNet + DenseNet) ISIC 2019 25,331 Acc. 0.92 / AUC 0.96 Ensemble learning achieved dermatologist-level accuracy. 10 Self-supervised Learning (SimCLR + Efficient Net) ISIC 2020 33,126 Acc. 0.93 / AUC 0.97 Pretraining on unlabeled data enhanced early detection accuracy. 11 Hybrid CNN–ViT ISIC 2020 + Derm7pt 20,000 Acc. 0.94 / Sens. 0.91 Hybrid model balanced feature locality and global attention. 12 Multi-modal AI (Image + Metadata) ISIC 2020 + Private 35,000 AUC 0.98 / Sens. 0.93 Combining patient metadata improved early melanoma detection. In conclusion, the early detection of skin cancer through dermoscopic image analysis is a critical component of effective clinical management [9]. The advent of artificial intelligence offers transformative potential by enhancing diagnostic accuracy, standardizing evaluations, and improving accessibility to expert-level assessments. While challenges related to data diversity, interpretability, ethics, and regulatory compliance remain, ongoing research and technological advancements continue to advance the integration of AI into clinical practice [10]. The synergistic combination of AI and clinician expertise holds promise for improving early detection rates, optimizing treatment outcomes, and ultimately reducing the morbidity and mortality associated with skin cancer (Table 2). As AI technologies continue to evolve, interdisciplinary collaboration among computer scientists, dermatologists, ethicists, and policymakers will be essential to ensure safe, effective, and equitable application in dermatological care [11]. 46 Eurasian J. Chem. Med. Pet. Res., (2026), Volume 5, Issue 1, 43-53 Table 2. Summary of Literature Trends Aspect Observation Evolution of Models Early studies (2017–2019) focused on CNNs; post-2020 shifted toward Efficient Net, Transformers, and hybrid/ensemble systems. Datasets The ISIC Archive and HAM10000 dominate; later works include multi-center datasets for generalization. Performance AUC values have improved from ~0.90 (2017) → ~0.98 (2024). Most models now match or exceed dermatologist-level performance. Key Innovation Integration of segmentation, self-supervised learning, and metadata fusion improved interpretability and sensitivity. Remaining Challenges Data imbalance, skin tone diversity, and real-world deployment validation still limit clinical translation. Methodology Study Design This study adopts a quantitative, retrospective approach to evaluate the effectiveness of artificial intelligence (AI) models in early detection of skin cancer through dermoscopic image analysis. The primary objective is to assess the diagnostic accuracy, sensitivity, and specificity of AI models in classifying dermoscopic images as benign or malignant. The study also examines the impact of dataset diversity and image preprocessing on model performance. Data Collection: Dermoscopic images were sourced from publicly available datasets, including the International Skin Imaging Collaboration (ISIC) archive, which provides high-resolution images of various skin lesions with expert-annotated labels. The dataset includes images representing multiple lesion types, including melanoma, basal cell carcinoma, squamous cell carcinoma, and benign nevi. Inclusion criteria:  High-resolution dermoscopic images (≥1024×1024 pixels).  Expert-verified lesion diagnosis.  Images covering diverse skin types and anatomical locations. Exclusion criteria:  Low-quality or blurred images.  Images with incomplete or ambiguous labels. Data Preprocessing Preprocessing is essential to enhance image quality and ensure consistency for AI training. The following steps were applied:  Resizing: All images were resized to 224×224 pixels to match the input requirements of convolutional neural networks (CNNs).  Normalization: Pixel intensity values were normalized to the range [0,1] to improve model convergence.  Data Augmentation: To increase dataset diversity and reduce overfitting, techniques such as rotation (±30°), horizontal/vertical flipping, and brightness adjustments were applied. AI Model Development: The study employs convolutional neural networks (CNNs) due to their proven effectiveness in image recognition tasks. Three architectures were evaluated:  ResNet50: A deep residual network designed to address vanishing gradient problems and capture hierarchical features.  InceptionV3: Optimized for multi-scale feature extraction through parallel convolutional layers.  DenseNet121: Features dense connectivity between layers to promote feature reuse and improve gradient flow. Each model was trained using the following parameters:  Optimizer: Adam, Learning rate: 0.0001  Batch size: 32, Epochs: 50  Loss function: Categorical cross-entropy The dataset was split into training (70%), validation (15%), and test (15%) sets. Model performance was evaluated on the test set using metrics including accuracy, sensitivity, specificity, F1-score, and area under the receiver operating characteristic curve (AUC-ROC) (Table 3). Table 3. Summary of Dataset Distribution Lesion Type Number of Images Training Set Validation Set Test Set Melanoma 1,200 840 180 180 Basal Cell Carcinoma (BCC) 1,000 700 150 150 Squamous Cell Carcinoma (SCC) 800 560 120 120 Benign Nevi 2,500 1,750 375 375 Total 5,500 3,850 825 825 47 Eurasian J. Chem. Med. Pet. Res., (2026), Volume 5, Issue 1, 43-53 AI Approaches for Skin Cancer Detection AI models for dermoscopic image analysis rely primarily on supervised learning methods, where algorithms are trained on large labeled datasets of skin lesion images. CNNs [12], a subset of deep learning models, are particularly effective in recognizing complex patterns and textures within images. Networks such as ResNet, VGGNet, and Inception have been applied to classify lesions as benign or malignant [13-15]. Data augmentation techniques, including rotation, scaling, and flipping, are commonly used to increase dataset diversity and improve model generalization. Additionally, ensemble learning methods, which combine predictions from multiple models, have shown improved diagnostic performance by reducing individual model biases [16]. Several studies have demonstrated the efficacy of AI in dermoscopic image analysis. Esteva et al. (2017) reported that a deep CNN trained on over 129,000 clinical images achieved dermatologist-level performance in classifying skin cancer, including melanoma and keratinocyte carcinoma [17]. Similarly, Haenssle et al. (2018) found that AI systems outperformed most dermatologists in a diagnostic competition, highlighting the potential of AI to enhance early detection. These findings underscore that AI can serve as a reliable adjunct tool in clinical decision-making, particularly for less experienced clinicians or in settings with limited dermatological expertise [18] (Table 4). Table 4. Hypothetical Dataset & Results Table Model / Approach Training Data (Images) Class Balance (Benign: Malignant) Accuracy Sensitivity (Recall) Specificity Precision F1-score AUC-ROC Inference Time (ms/image) Note 1. CNN (ResNet-34) 10,000 7k : 3k 0.89 0.84 0.92 0.78 0.81 0.93 45 Baseline model, solid starting point 2. MobileNetV2 (Lightweight) 10,000 7k : 3k 0.86 0.81 0.90 0.75 0.78 0.90 18 Fast and mobilefriendly 3. Ensemble (ResNet34 + EfficientNetB0) 10,000 7k : 3k 0.91 0.88 0.93 0.82 0.85 0.95 120 Strong accuracy, but slower 4. Vision Transformer (ViT-small) 10,000 7k : 3k 0.90 0.86 0.92 0.81 0.83 0.94 80 Needs large datasets; captures global patterns 5. U-Net (Segmentatio n) + SVM Classifier 10,000 7k : 3k 0.85 0.80 0.88 0.73 0.76 0.89 95 Useful when lesion boundaries are important 6. SVM with handcrafted features (Texture + Color) 3,000 2k : 1k 0.78 0.72 0.82 0.66 0.69 0.82 12 Works with small datasets but low accuracy 7. Fine-tuned EfficientNetB3 + Data Augmentatio n 20,000 14k : 6k 0.93 0.90 0.95 Explanation of Metrics  Training Data: Total number of images used to train the model [19].  Class Balance: Ratio of benign vs. malignant images. 48 Eurasian J. Chem. Med. Pet. Res., (2026), Volume 5, Issue 1, 43-53  Accuracy: Overall percentage of correctly classified samples.  Sensitivity (Recall): Ability to correctly detect malignant (positive) cases critical in cancer detection [20].  Specificity: Ability to correctly detect benign (negative) cases.  Precision: Proportion of predicted malignant cases that are actually malignant.  F1-score: Harmonic mean of precision and recall; useful for imbalanced data.  AUC-ROC: Model’s discrimination ability across thresholds [21].  Inference Time: Average prediction time per image useful for mobile/real-time use. Note: Key practical or interpretive remarks. Hypothetical Results Analysis  Sensitivity is the top clinical priority: In cancer detection, missing malignant cases (false negatives) is far more serious than false positives. → Models #7 and #3 have the best sensitivity (≥0.88).  Impact of data and augmentation: More data + augmentation improves all metrics (compare #1 vs. #7). EfficientNet-B3 with 20k images achieves the highest AUC (0.97).  Accuracy vs. Speed Trade-off: Ensemble models yield the best accuracy but are slower (120 ms per image). For mobile apps, Mobile Net (#2) provides a good balance.  Segmentation-based approaches: U-Net + SVM is useful for interpretability (providing lesion boundaries), though not the most accurate for pure classification tasks.  Traditional ML (SVM + handcrafted features): Performs decently on small datasets, but can’t match deep learning results serves mainly as a baseline.  AUC as a fair comparison metric: High AUC (> 0.95) indicates robustness across thresholds. Models #3 and #7 show excellent discriminative power. Practical Recommendations  Primary metric: Optimize sensitivity (recall) first; adjust threshold to ensure ≥ 0.90 sensitivity for safety.  Calibrate predictions: Use methods like Platt scaling or isotonic regression to produce well-calibrated probabilities.  Avoid data leakage: Split data patientwise, not image-wise, to prevent inflated performance.  Error analysis: Examine false negatives (missed malignancies) to identify common visual patterns.  External validation: Test models on independent datasets to verify generalization.  Deployment strategy:  For mobile: Mobile Net or quantized Efficient Net.  For clinical desktop: Ensemble or EfficientNet-B3 (Table 5). Table 5. Assume 2,000 test images (1,400 benign + 600 malignant) Outcome Predicted Malignant Predicted Benign Actual Malignant TP = 540 FN = 60 Actual Benign FP = 70 TN = 1330 Calculations:  Sensitivity = 540 / (540 + 60) = 0.90  Specificity = 1330 / (1330 + 70) ≈ 0.95  Accuracy = (540 + 1330) / 2000 = 0.935 Challenges and Limitations Despite promising results, several challenges remain in deploying AI for skin cancer detection. First, the availability of large, diverse, and high-quality datasets is limited [22], particularly for rare skin cancer subtypes and images from diverse ethnic populations. Models trained on homogeneous datasets may exhibit reduced generalizability and potential bias when applied to underrepresented groups. Second, interpretability of AI models remains a concern. While CNNs can achieve high accuracy, their decision-making processes are often opaque, which may limit clinical trust and adoption. Methods such as saliency maps and Grad-CAM have been proposed to provide visual explanations of model predictions, but these techniques are still under development [23]. Integration of AI into clinical practice also raises regulatory and ethical considerations. Ensuring patient privacy, obtaining informed consent for the use of medical images, and complying with healthcare regulations are essential for responsible deployment [24]. Furthermore, AI should not replace clinical judgment but rather function as an assistive tool that augments dermatologists’ expertise. Continuous monitoring, validation, and updating of AI models are necessary to maintain 49 Eurasian J. Chem. Med. Pet. Res., (2026), Volume 5, Issue 1, 43-53 performance in real-world clinical environments [25]. Discussion Early detection of skin cancer, particularly melanoma, remains one of the most critical challenges in dermatology. The accuracy and timeliness of diagnosis significantly influence patient survival rates and treatment outcomes. Traditional diagnosis relies heavily on expert dermatologists who visually inspect dermoscopic images a process that can be subjective, timeconsuming, and dependent on physician experience. In recent years, Artificial Intelligence (AI), especially Deep Learning (DL), has revolutionized this field by enabling automated and highly accurate analysis of dermoscopic images [26-28]. This section provides an analytical discussion of the current progress in AI-based skin cancer detection, compares major approaches from the literature, and highlights emerging trends, advantages, and limitations of various methodologies [29]. Overall Research Trends The evolution of AI in dermoscopic image analysis can be divided into three key phases:  Classical CNN dominance (2016–2019): Early works (e.g., Esteva et al., 2017; Haenssle et al., 2018) demonstrated that deep convolutional neural networks (CNNs) such as Inception-v3 and ResNet could match or exceed dermatologist-level accuracy using large datasets like ISIC and HAM10000 [30].  Model optimization and ensemble learning (2020–2022): Researchers began employing architectures such as Efficient Net and Dense Net, along with ensemble strategies that combined multiple models for improved robustness and generalization [31-33].  Emerging hybrid and transformerbased approaches (2021–present): Vision Transformers (ViTs), hybrid CNN ViT architectures, and self-supervised models have shown strong potential in capturing both local and global features of dermoscopic images [34]. The following table summarizes representative studies and their key findings (Table 6). Table 6. Summary of Selected Research Studies No. Model / Method Dataset Images (Approx.) Main Metric (Accuracy / AUC / Sensitivity) Key Findings 1 Inception-v3 CNN ISIC + DermNet 129,000 AUC 0.96 First large-scale study proving CNNs can reach dermatologistlevel accuracy. 2 ResNet-50 HAM10000 10,015 AUC 0.95 CNN outperformed 58 dermatologists in melanoma classification. 3 Ensemble (ResNet + Inception) ISIC Archive 25,000 AUC 0.94 Ensemble improved model stability and reduced overfitting. 4 EfficientNet-B0 HAM10000 + PH2 12,000 Accuracy 0.91 Transfer learning enhanced performance on small datasets. 5 Vision Transformer (ViTsmall) ISIC 2020 33,000 AUC 0.93 Transformers captured global lesion structure better than CNNs. 6 U-Net + SVM PH2 2,000 Accuracy 0.84 Combined segmentation and classification improved interpretability. 7 CNN + Bayesian Optimization HAM10000 10,015 Accuracy 0.90 Automated hyper parameter tuning enhanced precision. 8 Ensemble (ResNet + DenseNet) ISIC 2019 25,331 AUC 0.96 Ensemble models achieved dermatologist-level performance. 9 Self-supervised EfficientNet ISIC 2020 33,126 AUC 0.97 Self-supervised pretraining improved early-stage detection. 10 Hybrid CNN–ViT ISIC + Derm7pt 20,000 Accuracy 0.94 Hybrid models balanced local and global feature extraction. 50 Eurasian J. Chem. Med. Pet. Res., (2026), Volume 5, Issue 1, 43-53 11 Multi-modal AI (Image + Metadata) ISIC + Private 35,000 AUC 0.98 Integrating clinical metadata boosted diagnostic sensitivity. 12 EfficientNet-B3 + Explainable AI ISIC 2020 30,000 AUC 0.97 Improved interpretability using attention heat maps for clinical decision support. Comparative Analysis Performance and Accuracy: Across most studies, AUC scores range between 0.93–0.98, which is comparable to or even exceeds human dermatologist accuracy. Early CNN-based models such as Inception-v3 demonstrated feasibility but required massive datasets for reliable generalization. Later models (Efficient Net, Transformer, and Hybrid networks) achieved similar or better results with fewer images due to improved architectures and data augmentation strategies [35]. Sensitivity and Clinical Relevance: In clinical settings, sensitivity (recall) is the most critical metric since missing a malignant lesion can have severe consequences. Studies like Haenssle et al. (2018) and Kumar & Lee (2024) report sensitivity values above 0.90, confirming that AI can reliably identify malignant cases. However, some high-accuracy models still suffer from false positives, which can cause patient anxiety or unnecessary biopsies [36]. Interpretability and Trust: Interpretability remains a significant challenge. Traditional CNNs act as “black boxes,” providing no insight into their decision-making. Data and Generalization Issues: Most datasets (e.g., ISIC, HAM10000) are biased toward lighter skin tones, limiting model generalization to darker skin populations. Some recent works propose data balancing, domain adaptation, and synthetic image generation (GAN-based) to mitigate this issue. However, external multi-center validation is still rare, which remains a bottleneck for clinical deployment [37]. Computational Efficiency: While ensemble and transformer models deliver superior accuracy, they often require high computational resources, which restricts their use in low-resource settings. Lightweight architectures like MobileNetV2 achieve slightly lower accuracy but are ideal for real-time or mobile screening applications critical in rural or telemedicine contexts (Table 7). Table 7. Strengths and Weaknesses of AI-based Systems Aspect Strengths Weaknesses / Limitations Accuracy AI models can achieve dermatologist-level or superior accuracy (AUC > 0.95). Dependent on large annotated datasets; may not generalize to unseen populations. Speed & Scalability Instantaneous diagnosis; useful for mass screening. Requires hardware acceleration (GPU/TPU). Consistency Eliminates inter-observer variability. May propagate dataset biases if not corrected. Interpretability Explainable AI methods (Grad-CAM, segmentation) improve trust. Still limited understanding of internal feature representation. Deployment Mobile and cloud-based AI systems support tele dermatology. Data privacy, regulatory approval, and liability remain unresolved. Comparison with Similar Studies Compared with earlier meta-analyses (e.g., Tschandl et al., 2019; Brinker et al., 2020), the latest studies show a consistent upward trend in AUC, accuracy, and robustness. Ensemble and hybrid models yield the best balance between sensitivity and specificity. Furthermore, self-supervised learning has proven especially effective for early detection, allowing the use of unlabeled images to pretrain networks and reduce annotation costs [38]. In contrast to these approaches, multi-modal system integrate dermoscopic images with patient metadata such as age, gender, and lesion location which improves contextual understanding. This integration enhances diagnostic accuracy by roughly 3–5% compared to image-only models. The proposed 2025 conceptual model builds on these findings by integrating explainable AI tools for clinical transparency, enabling physicians to visualize the model’s decision path. Key Challenges and Future Directions  Dataset Diversity and Fairness: Global data sharing and inclusion of underrepresented skin tones are essential to ensure fairness and inclusivity in AI-based diagnosis.  Clinical Validation: Most models are validated on benchmark datasets; largescale, prospective, and multi-center clinical 51 Eurasian J. Chem. Med. Pet. Res., (2026), Volume 5, Issue 1, 43-53 trials are needed before real-world deployment.  Model Explain ability and User Trust: Physicians require interpretable and transparent systems that show why a decision was made. Future work should integrate explainable AI (XAI) methods like attention visualization or feature attribution maps.  Regulatory and Ethical Concerns: Legal responsibility for misdiagnosis, patient privacy, and bias mitigation must be addressed before AI tools are approved for clinical use.  Edge and Mobile Deployment: Lightweight models (Mobile Net, quantized Efficient Net) can democratize access in low-resource areas, supporting early detection at the community level. Artificial intelligence has profoundly transformed the landscape of early skin cancer detection through dermoscopic image analysis. From early CNNbased systems to today’s hybrid and transformerbased frameworks, the field has achieved dermatologist-level diagnostic performance. However, several challenges remain: limited dataset diversity, lack of real-world validation, and the need for transparent, interpretable models. The future of AI in dermatology lies in multi-modal integration, explainable systems, and clinical validation across populations. By addressing these issues, AI-driven tools can transition from experimental success to trusted, real-world clinical assistants ultimately reducing mortality through faster, more accurate, and more accessible early detection of skin cancer [39]. Future Directions Future research should focus on addressing the limitations of current AI systems. Multi-center collaborations and the development of large, diverse datasets can improve model robustness and reduce bias. Incorporating multimodal data, such as patient history, genetic information, and lesion metadata, may enhance diagnostic accuracy and provide more comprehensive risk assessments. Advances in explainable AI will further facilitate clinical adoption by allowing clinicians to understand and trust model decisions. Additionally, integration with mobile ceroscopy devices and telemedicine platforms can expand access to early skin cancer detection, particularly in remote or underserved areas. Emerging AI techniques, such as federated learning, offer opportunities to train models across decentralized datasets while preserving patient privacy. These approaches enable collaboration among institutions without sharing sensitive data, addressing a critical barrier in healthcare AI development. Moreover, combining AI with clinical decision support systems can facilitate personalized treatment recommendations and improve patient outcomes [40]. Conclusion Artificial intelligence represents a transformative tool in the early detection of skin cancer through dermoscopic image analysis. By leveraging deep learning and advanced image processing techniques, AI can identify malignant lesions with high accuracy, complementing dermatologists’ expertise and enhancing diagnostic efficiency. While challenges related to dataset diversity, model interpretability, and ethical deployment remain, ongoing research and technological advancements are rapidly addressing these issues. The integration of AI into dermatological practice has the potential to improve early detection, reduce diagnostic errors, and optimize healthcare resources, ultimately leading to better patient outcomes. As AI continues to evolve, collaborative efforts among researchers, clinicians, and regulatory bodies will be essential to ensure its safe, effective, and equitable application in skin cancer diagnostics. Disclosure Statement No potential conflict of interest reported by the authors. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or notfor-profit sectors. Authors' Contributions All authors contributed to data analysis, drafting, and revising of the paper and agreed to be responsible for all the aspects of this work. References [1] Ahmad, N., Shah, J. H., Khan, M. A., Ansari, G. J., Tariq, U., Kim, Ye Jin, & Cha, J.-H. (2023). A novel framework of multiclass skin lesion recognition from dermoscopic images using deep learning and explainable AI. Frontiers in Oncology, 13. [2] Ameri, A. (2020). A Deep Learning Approach to Skin Cancer Detection in Ceroscopy Images. Journal of Biomedical Physics & Engineering, 10(6), 801-806. [3] Bajovic, M. (2021). Meta-moral cognition: Bridging the gap among adolescents' moral thinking, moral emotions, and moral actions. Journal of Moral Education, 50(3), 303–319. [4] Berkowitz, M. W., & Grych, J. H. (1998). Early development of moral emotions and moral